Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion

Industry Insight by 2FIRSTS, edited by Sophia
Apr.08.2024
Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion
EVO NXT Interview: 2FIRSTS discussed nicotine pouch market trends with NNPA.EU leaders Jonas Lundqvist and Rebert Casinge.

Recently, at the EVO NXT tobacco exhibition in Spain, 2FIRSTS engaged in a deep discussion with Jonas Lundqvist, CEO of the Nordic Nicotine Pouches Alliance (NNPA.EU), and Robert Casinge, Editor-in-Chief of pouchforum.eu, about the trends, regulations, and future development of the nicotine pouch market. The NNPA.EU, headquartered in Brussels, has been studying the trends in oral tobacco consumption for 20 years.

 

Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion
Jonas Lundqvist (left) and Robert Casinge (right) | Image source: 2FIRSTS

 

EU Market is Experiencing Robust Growth

 

According to data, the number of nicotine pouch users in the European Union is steadily increasing, reaching 2.6 million. The adult usage rate is 0.7%, with an annual growth rate of 7%. This trend indicates a continued interest and acceptance among consumers for this product. Nicotine pouches overlap with traditional cigarettes, especially among users seeking reduced harm alternatives.

 

In terms of market, the European Union has over 90 nicotine pouch brands, with main producing countries including Sweden, Denmark, Hungary, Poland, Italy, and the Czech Republic. The majority of sales channels are offline, accounting for 68%, while online sales make up 32%. Forecasts indicate that by 2027, the nicotine pouch market value is expected to reach 15-16 billion euros, potentially even reaching 21 billion euros, provided that the policy environment remains favorable.

 

Regulatory Challenges to be Addressed

 

However, the nicotine pouch market also faces regulatory challenges. While most European Union countries consider it a general consumer product, there are still some countries that classify it as a tobacco product or a medicine/food product.

 

For example, the number of snus (nicotine pouch) users in Sweden is similar to the EU average, but the proportion of cigarette smokers is lower (5-6%), especially among young people, leading the World Health Organization to consider Sweden a smoke-free country. However, 9 EU countries classify nicotine pouch as a tobacco-related product, 4 as a medicine/food, and most countries (14) consider it a general consumer product.

 

As the host country of this exhibition, Spain's policies are unclear, while Bulgaria and Greece have specific tax policies on nicotine pouches.

 

Although the European Union has not yet established specific regulations, signs indicate that it may include it in the Tobacco Products Directive in the future. Of particular note is that Nordic governments are actively strengthening regulation of nicotine pouches, with Finland recently legalizing them as smoking cessation aids and imposing restrictions on sales to curb illegal smuggling and sales.

 

Public Attitudes Divide, Caution Needed in Product Innovation

 

There is a certain amount of disagreement in public attitudes. A public opinion consultation by the European Commission showed that the public and health organizations generally support nicotine pouches as a smoking cessation tool, but regulators are cautious about their health impacts. For example, it is deemed acceptable for each nicotine pouch to contain 20mg of nicotine, and products with high nicotine content should not exceed 50mg.

 

The popularity of nicotine pouches is mainly due to their simple and convenient nature - no charging or e-liquid is required, making them easy to carry and suitable for replacing traditional cigarettes. However, the issues of product flavor and market demand should not be overlooked. Manufacturers need to be cautious of flavors that may appeal to children, and strengthen the control and balance of chemical ingredients.

 

Therefore, although the nicotine pouch market is showing strong momentum in growth, regulatory disputes and public concerns are still ongoing. The key to future development lies in changes in the policy environment and the improvement of market innovation capabilities.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
The UK High Court has ordered Chinese vape manufacturer Shenzhen SKE Technology to provide £569,039 ($776,000) in security for costs in its design infringement proceedings against Vapepen London and other defendants over its Crystal Bar vape product. The court did not accept the defendants’ main argument that recovering costs from a China-based company would face significant enforcement obstacles, but found that SKE had not sufficiently disclosed its own financial position. The order is procedural and does not determine the underlying infringement claims.
News
Aug.21
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
R.J. Reynolds Vapor Company has introduced Vuse Pro prefilled pods in Peach, Berry, Watermelon and Fresh Mint in selected U.S. states. Vuse’s U.S. website says the pods are intended for use with existing Vuse Alto devices. Each contains 2.0 mL of e-liquid at 5.0% nicotine by weight, uses nicotine salts and is offered in two- and four-pod packs. Reynolds said the rollout includes mandatory ID scanning for every purchase, purchase limits, stronger retailer-accountability requirements and strict age-restricted marketing standards. The four pods have not received marketing authorization from the U.S. Food and Drug Administration.
Sep.10
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13